Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 7/20 | 0.40 |
| ▸ | FSCN1 | Q16658 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.36 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.36 |
| ▸ | MET | P08581 | 1/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.35 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2943245 | 0.89 | FSCN1 (0.42) | PPARGFSCN1HDAC1METPDE10A | |
| SCHEMBL4807506 | 0.89 | PPARG (0.37) | PPARGFSCN1HDAC1NTRK1MET | |
| SCHEMBL4806499 | 0.87 | TRPV3 (0.39) | PPARGFSCN1 | |
| SCHEMBL4799915 | 0.86 | TRPV3 (0.38) | PPARGFSCN1HDAC1NTRK1MET | |
| SCHEMBL4799992 | 0.86 | PPARG (0.43) | PPARGFSCN1HDAC1HDAC6HDAC4 | |
| SCHEMBL4805925 | 0.86 | PPARG (0.40) | PPARGFSCN1HDAC1HDAC6HDAC4 | |
| SCHEMBL4807596 | 0.86 | PPARG (0.38) | PPARGFSCN1HDAC1NTRK1MET | |
| SCHEMBL2949469 | 0.85 | FSCN1 (0.42) | PPARGFSCN1HDAC1NTRK1MET | |
| SCHEMBL4802934 | 0.84 | FSCN1 (0.38) | PPARGFSCN1MET | |
| SCHEMBL4807232 | 0.84 | PPARG (0.42) | PPARGFSCN1HDAC1NTRK1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7468375-B2 | Inhibitors of the HIV integrase enzyme | PFIZER INC. (US) | 2008-12-23 | — | — | US | claimed |
| EP-1756103-A2 | PYRROLOPYRIDINE DERIVATIVES AND THEIR USE AS HIV-INTEGRASE INHIBITORS | Pfizer, Inc. (US) | 2007-02-28 | — | — | EP | claimed |
| US-20050277662-A1 | Inhibitors of the HIV integrase enzyme | AGOURON PHARMACEUTICALS, INC | 2005-12-15 | — | — | US | claimed |
| WO-2005103003-A2 | PYRROLOPYRIDINE DERIVATIVES AND THEIR USE AS HIV-INTEGRASE INHIBITORS | PFIZER INC. (US) | 2005-11-03 | — | — | WO | claimed |
| US-7468375-B2 | Inhibitors of the HIV integrase enzyme | PFIZER INC. (US) | 2008-12-23 | — | — | US | disclosed |
| US-7468375-B2 | Inhibitors of the HIV integrase enzyme | PFIZER INC. (US) | 2008-12-23 | — | — | US | disclosed |
| US-7468375-B2 | Inhibitors of the HIV integrase enzyme | PFIZER INC. (US) | 2008-12-23 | — | — | US | disclosed |
| EP-1756103-A2 | PYRROLOPYRIDINE DERIVATIVES AND THEIR USE AS HIV-INTEGRASE INHIBITORS | Pfizer, Inc. (US) | 2007-02-28 | — | — | EP | disclosed |
| US-20050277662-A1 | Inhibitors of the HIV integrase enzyme | AGOURON PHARMACEUTICALS, INC | 2005-12-15 | — | — | US | disclosed |
| WO-2005103003-A2 | PYRROLOPYRIDINE DERIVATIVES AND THEIR USE AS HIV-INTEGRASE INHIBITORS | PFIZER INC. (US) | 2005-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050277662-A1 | Inhibitors of the HIV integrase enzyme | IMPDH1, INTS9, TYMP | PPARG 4290/4885FSCN1 4841/4885HDAC1 626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.